Grow Group PLC renews medical cannabis market access agreement with Aurora

 said late on Thursday that it has extended a strategic relationship with Canadian firm Aurora Cannabis Inc (NYSE:ACB) by signing a two-year market access services agreement for the UK, following an initial agreement in 2019.

Grow, which is focused on making cannabis-based medicines accessible to patients in the UK and Europe, also said it is currently raising £6mln of capital and will have some remaining allocation for sophisticated investors or high net worth investors.

READ: UK cannabis industry growing like a weed, report reveals

“Everything we do is with the patient in mind. Addressing patients’ needs and broadening access to medical cannabis in the UK is at the heart of Grow’s strategy,” said Pierre van Weperen, managing director of Grow Group in the UK & Ireland.

He added: “Quality of products, broad range of offerings and a strong supply chain is critical to serving the UK’s fast-growing patient population. Partnering with companies like Aurora will continue to enable us to offer a portfolio of high-quality flowers and extracts to doctors and the patients who will benefit from them. Every day, these products make a difference for patients, and we look forward to advancing market access together with Aurora.”

Aurora Cannabis chief executive Miguel Martin said the company has worked successfully with Grow and their joint venture partner, IPS, since entering the UK market. 

“Renewing this agreement will help to broaden access for patients by leveraging Grow’s work educating physicians and creating awareness of medical cannabis options. Aurora is committed to providing access to legally produced high-quality pharmaceutical-grade medical cannabis to address the needs of the growing European medical cannabis market, made possible with our EU GMP facility, Aurora Nordic,” he added.

Grow Group expects the capital raise to be completed in mid-June.